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1. INTRODUCTION
Colorectal cancer (CRC) is the second most common cancer type 
among females and the third among males; there were 1.4 mil-
lion new cases and 639 000 deaths in 2012 according to reports. 
High alcohol consumption, obesity, smoking, physical inactivity, 
age, and family history are some of the risk factors for CRC, 
leading to the increase in the rate of CRC in recent years.1,2 
Unfortunately, due to the late manifestation of CRC symptoms, 
patients develop metastasis; that is why CRC is considered as 
one of the deadliest cancer types. Thus, screening programs have 
important roles in reducing the incidence and mortality of CRC. 
Several potential screening tests are currently used to detect 
CRC such as colonoscopy, flexible sigmoidoscopies, guaiac-
based fecal occult blood tests, and fecal immunochemical tests. 
Colonoscopy is a golden test, but its invasive manner and high 
cost limit its application. On the other hand, these methods suf-
fer from different problems including invasive, expensive, low 
sensitivity, and low specificity nature.3–5 In 2008, the American 
Cancer Society declared a guideline that emphasized the impor-
tance of screening tests that facilitate prevention of cancer by 
early detection of the disease. The attempt of the scientific inves-
tigation has thus changed to finding noninvasive markers from 
biofluids such as blood, urine, and saliva.6
MicroRNAs (miRNAs) are short noncoding RNAs that regu-
late gene expression by either mRNA degradation or translational 
repression. In fact, 30% of human genes are regulated by miRNAs; 
a miRNA can regulate hundreds of different protein coding genes.7 
miRNAs have important roles in biological processes involved in 
carcinogenesis including apoptosis, proliferation, organ morphol-
ogy, and developmental transitions. The miRNA expression has 
been shown to aberrantly change in different types of cancers 
including lung, pancreas, thyroid, breast, and colon.8 New findings 
on miRNAs have recently shed light over cancer-related researches, 
especially the field of biomarkers.9 Reports have successfully 
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Abstract
Background: Extracellular vesicles (EVs) are a heterogeneous group of membrane-bound vesicles with complex cargoes includ-
ing proteins, lipids, and nucleic acids. EVs have received significant attention due to their specific features including stability under 
harsh conditions and involvement in cell-to-cell communication. Circulating EVs and the molecules associated with them are 
important in the diagnosis and prognosis of cancers. MicroRNAs (miRNAs) are a group of small noncoding RNAs that have a role 
in regulating gene expression. Current literature shows that circulating miRNAs can be used as noninvasive biomarkers for early 
detection of cancers. The present study was set to investigate the potential role of serum exosomal miRNA expression levels in 
colorectal cancer (CRC) patients and evaluate their correlation with clinicopathologic features.
Methods: Exosome-enriched fractions were isolated from the serum of 25 CRC patients and 13 age- and sex-matched healthy 
controls using a polymer-based precipitation method. During the pilot phase, real-time polymerase chain reaction (RT-PCR) was 
carried out on 12 CRC patients and eight healthy participants to evaluate the expression difference of 11 candidate miRNAs 
between CRC patients and tumor free subjects. Finally, the results were validated in a separate group, which was similar in size 
to the pilot group. The clinicopathologic data were also collected and the relationship between aberrant miRNA expression and 
clinicopathological parameters were investigated.
Results: There were high expressions of exosomal miR-23a and miR-301a in serum samples of CRC patients compared to nor-
mal controls in training and validation phases; these differences were not significantly correlated with clinicopathologic features. 
Receiver operating characteristic curve analysis showed that miR-301a and miR-23a were able to discriminate CRC patients from 
normal subjects.
Conclusion: The findings provide evidence on the roles of miR-301a and miR-23a in CRC development and their potential roles 
as noninvasive biomarkers for early detection of CRC.
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shown that miRNAs can act as reliable diagnosis biomarkers 
in tissue samples from different types of cancers; however, there 
are some problems about collecting tissue samples. On the other 
hand, most researchers have focused on finding noninvasive tools 
for detecting different cancers. In this context, circulating nucleic 
acids have received considerable attention. A primary study was 
conducted by Chen et al (2008), which demonstrated that miR-
NAs are stable in serum in harsh conditions such as low or high 
pH, freezing and thawing cycles, long-time storage, boiling, and 
RNase digestion.10 Although there are some reports on their pro-
tective mechanisms, the exact mechanism is still unknown. There 
are some models for stability including formation of Argo-miRNA 
complex and/or encapsulation in exosomes. Several reports have 
distinctly demonstrated that cells actively secrete miRNAs to the 
extracellular environment by exosomes and function as bio mes-
sengers in the communication among cells.11–13 Malignant cells also 
release exosomes containing miRNAs, which may play important 
roles in tumor progression.14,15 In this regard, the scientific com-
munity is recently interested in finding noninvasive biomarkers in 
extracellular vesicle (EV) cargoes for early detection of cancers, 
predicting the responses to different types of treatments, and better 
understanding the tumor prognosis.
The current knowledge suggests that expression profile of 
miRNAs in serum may reflect the miRNA profile of tumor. 
Despite the results of previous reports suggesting that several 
miRNAs are aberrantly expressed in CRC, there are still not 
enough data on the description of serum exosomal miRNAs in 
CRC and the correlation between serum exosomal miRNAs and 
clinicopathologic features of CRC. Accordingly, in this study, 
11 top deregulated miRNAs were examined in terms of their 
potential roles as a reliable, cost-effective, and efficient screening 
method for CRC.
2. METHODS
2.1. Patient and sample processing
Cases with positive colonoscopy results for CRC, confirmed 
by histology as colon, rectum, or sigmoid, were referred to 
Amiralmomenin Hospital of Tabriz, Iran. Patients with a history of 
chemotherapy and radiotherapy, familial adenoma, and malignant 
tumors were excluded from the study. All patient samples were his-
tologically confirmed, and the stage of the tumor was determined 
according to surgery findings using TNM (tumour, node, metasta-
ses) staging system. Control participants were selected from indi-
viduals undergoing colonoscopy with negative results for polyp, 
malignancy, and other gastrointestinal complaints, matching to the 
patients’ age, gender, and ethnicity. Detailed questionnaires includ-
ing informed consent and questions on clinical and family history 
were obtained from the participants. The study was approved by 
the Research Ethics Committee of Tabriz University of Medical 
Sciences. Blood samples were collected from the patients and 
healthy participants before the surgery and 1 hour after colonos-
copy, respectively. After filling out the consent forms, 10 mL of the 
blood samples was transferred into clot activator serum tubes, 
which were immediately placed on ice. The tubes were centrifuged 
at 2000g for 10 minutes. The supernatant was transferred into 
new tubes and centrifuged at 2500g for another 10 minutes. Serum 
samples were collected, were aliquoted into Eppendorf tubes, and 
were stored at −80°C until use. The time span from sample collec-
tion to storage at −80°C was <2 hours. Each sample underwent not 
more than two freeze-thaw cycles before the analysis.
2.2. Exosome isolation and characterization
Exosome-enriched fractions were isolated from 500 µL serum 
by ExoQuick reagent (System Biosciences Inc., Mountain View, 
CA, USA), and exoRNA purification was performed using the 
SeraMir Exosome RNA Amplification kit (System Biosciences 
Inc., Mountain View, CA, USA) according to the manufacturer’s 
instruction. The obtained exoRNA was quantified by spectro-
photometry at 260 nm. After isolation, the exosome pellet was 
resuspended in Phosphate buffered saline (PBS) and submitted 
to several analyses to control the purity and yield, and they were 
then stored at −80°C until further use.
During the initial step of exosome characterization, an 
ExoELISA kit (System Biosciences Inc., Mountain View, CA, 
USA) was used to detect exosomal markers, including CD9 and 
CD63 in an Enzyme-Linked ImmunoSorbent Assay (ELISA) 
assay. Subsequently, the western blot was used to character-
ize exosomal markers. Briefly, the protein concentration of the 
precipitated exosomes was measured by BCA Protein Assay Kit 
with BSA as standard according to manufacturer’s instruction 
(Pierce, Thermo Scientific, Rockford, IL, USA). Equal amounts 
of protein were used in western blot analysis. The samples were 
loaded on sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred onto Polyvinylidene dif-
luoride (PVDF) membrane. The following primary antibodies 
were used: CD81 (Santa Cruz Biotechnology, Santa Cruz, CA) 
and TSG-101 (Abcam, Cambridge, UK). Afterward, proteins 
were visualized using enhanced chemiluminescence System. 
Finally, exosome-enriched fractions were submitted to nano-
particle tracking analysis (NTA). NTA provides information on 
particle size distribution of samples in liquid suspension using 
the properties of Brownian motion and light scattering. The con-
centration and size distribution of particles were evaluated by 
NTA according to manufacturer’s instruction.
2.3. Screening of candidate miRNAs by quantitative real-
time polymerase chain reaction
In this study, a total of 11 candidate miRNAs (miR-23a, miR-
92a, miR-221, miR-301a, miR-31, miR-143, miR-142, miR-223, 
miR-18a, miR-135b, and miR-18b) were selected on the basis of 
the most reported deregulated miRNAs.16 Each 500 µL of serum 
yielded 50 µL of total RNA, which was kept at a temperature of 
−80°C. Reverse transcription and quantitative polymerase chain 
reaction (qPCR) were performed on equal RNA volumes of each 
sample using SeraMir Exosome RNA Amplification kit (System 
Biosciences Inc., Mountain View, CA, USA) according to the 
manufacturer’s protocol. Briefly, 5 µL of the total RNA was poly-
adenylated and reverse transcribed to cDNA using the kit; 10 µL 
of this product was used in adaptor anneal reaction. Finally, 5 µL 
of this product was used for further polymerase chain reaction 
(PCR) analysis. PCR was performed by SYBR® Green Suppermix 
kit (Takara, Dalian, China) in a Roche PCR system. The primers 
used in the study were manufacturer-provided universal primers 
and miRNA-specific forward primers (System Biosciences Inc., 
Mountain View, CA, USA). Each reaction was performed in a 
total of 12 µL volume, and 45 PCR cycles were used as follows: 
denaturation at 95°C for 30 seconds, denaturation for 15 sec-
onds at 95°C, and extension at 60°C for 1 minute. Melting curve 
analysis was also used to explore the specificity of the expected 
PCR. Each reaction was performed in triplicate, and one reaction 
was used without template as the negative control. Cycle thresh-
old (Ct) value of ≥38 was considered as a low expression. Relative 
quantification of miRNAs was performed using the comparative 
Ct method software provided by the manufacturer.
2.4. Validation of differentially expressed miRNAs
The separate group of cases and controls (13 CRC patients and 
five tumor-free subjects) were used to validate differentially 
expressed miRNAs from the screening step.
2.5. Statistical analysis
All calculations were performed using GraphPad Prism 7.01 
(GraphPad Software, Inc., La Jolla, CA, USA). Student’s t-test, 
one and two-way analysis of variance, and chi-squared test were 
used for data analysis. p-value of <0.05 was considered to be 
statistically significant. Receiver operating characteristic (ROC) 
curve and the area under the ROC curve (AUC) were used to 
assess the sensitivity and specificity of miRNA biomarkers for 
the diagnosis of CRC.
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3. RESULTS
3.1. Patient population
The present study utilized the sera derived from the follow-
ing: who were diagnosed with CRC (n = 25), matching age 
and gender to participants with no evidence of CRC (n = 13). 
All 25 patients were pathologically and clinically diagnosed 
with CRC (Table). No significant difference was observed on 
the distribution of age (p = 0.51), gender (p = 0.76), alcohol 
consumption (p = 0.82), smoking (p = 0.93), and other dis-
eases (p = 0.62) between the CRC patients and tumor-free 
subjects.
3.2. Characterization of exosome-enriched fraction
According to NTA, more particles were observed in exosome-
enriched fraction isolated from serum and cell-derived exosomes 
in comparison with PBS and exosome-free medium. The levels 
of tested vesicle markers (CD63 and CD9) by ELISA were also 
higher in cell-derived exosome and the exosome-enriched frac-
tions isolated from serum compared to exosome-free medium, 
which is consistent with western blotting results, confirm-
ing the presence of EVs in the isolated samples (Fig.  1A–C). 
Electrophoresis of the protein content of the exosomes isolated 
by Exo-Quick also revealed that the tested samples shared a 
similar mixture of proteins. Moreover, RNAs were separated by 
size, representing the presence of a population of small RNAs. 
The 18S and 28S ribosomal RNAs were hardly observed, gen-
erally detected with cell-derived RNAs. The examination of 
miRNA concentrations in the serum samples from the tested 
samples showed that miRNAs are the important components of 
small RNAs in serum.
3.3. Circulating miRNA screening
Newly diagnosed CRC patients from Amiralmomenin Hospital 
of Tabriz, Iran, were included in the study. A two phase case-
control study was designed to identify serum miRNAs as blood-
based biomarkers for CRC diagnosis. We selected 11 candidate 
miRNAs reported in previous studies and used quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) 
assays to investigate their expression in the 12 CRC cases and 
age- and gender-matched eight tumor-free samples in the training 
set. miR-301a and miR-23a presented a detection rate of >90% 
in both CRC and tumor-free samples, and were selected for fur-
ther analysis. Statistical analysis revealed miR-301a (3.1 times 
upregulated) and miR-23a (3.8 times upregulated) that have sig-
nificantly different levels in CRC patients compared to healthy 
controls (p < 0.0001) (Fig. 2). ROC curve analysis was also used 
to examine the diagnostic potential of differentially expressed 
miRNAs to distinguish between the cancer and normal groups. 
AUC values for miR-23a (p < 0.05; 95% CI: 0.74-1.0) and miR-
301a (p < 0.05; 95% CI: 0.65-1.0) in discriminating CRC patients 
from healthy controls were 0.89 and 0.84, respectively, which 
showed that serum levels of miR-23a and miR-301a were sensi-
tive biomarkers for discriminating CRC patients from healthy 
samples (Fig. 3). In addition, miR-92a showed upregulation in 
patients, although it was not statistically significant; it tended to 
be higher in CRC patients. The levels of other tested miRNAs in 
serum were too low to be quantified accurately. qRT-PCR is the 
most sensitive and reproducible method to quantify gene expres-
sion, but the accuracy is limited provided that the expression of 
miRNAs is low. As a result, some miRNAs with a low expression 
cannot be tested or compared between the patients and healthy 
controls. Subsequently, we tried to correlate expression levels 
of analyzed miRNAs to clinical-pathological characteristics of 
CRC patients. No significant difference was observed in the 
expression levels of miR-301a and miR-23a in the serum of CRC 
patients according to age and gender as well as tumor type, size, 
and location. Taken together, it was hypothesized that miR-301a 
and miR-23a contribute to CRC pathogenesis. Hence, it was 
investigated whether these two miRNAs would show altered 
expression levels in different sets of samples. Validation of dif-
ferentially expressed miRNAs (miR-23a and miR301a) detected 
by the pilot study performed on a separate group (13 cases and 
five controls) confirmed the significant overexpression of miR-
23a (>3-fold times) and miR-301a (>3-fold times) in the case 
subjects compared to the controls. miR-92a and miR-21 were 
also included in this phase because they have been reported as 
biomarkers for CRC. Additionally, a high expression of miR-92a 
and miR-21 has been identified in other cancer types, which pro-
posed that further studies are necessary to reveal their potential 
roles as cancer biomarkers.17–19 Surprisingly, the detection rate of 
Table
Clinicopathological features of CRC patients
Characteristics CRC patients, n (%)
Age, y (mean) 58.7
Gender  
 Female 10 (40)
 Male 15 (60)
Location  
 Cecum 5 (20)
 Terminal ileum 9 (36)
 Sigmoid colon 5 (20)
 Rectum 6 (24)
Size, cm  
 ≥4 10 (40)
 ˂4 15 (60)
TNM stage  
 II 12 (48)
 III 13 (52)







CRC = colorectal cancer.
Fig. 1 Characterization of isolated extracellular vesicles (EVs). A, Isolated EVs were evaluated for the expression of EV markers TSG-101 and CD 81 by western 
blotting. B, Analysis of EV markers by ELISA. C, Evaluation of the EV concentration by nanoparticle tracking analysis (NTA).
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miR-21 and miR-92a was <60% in either CRC or healthy group; 
they were excluded from the analysis. Our results indicated that 
in CRC, the primary tumor releases high concentrations of miR-
NAs into the blood circulation, and some of them were found in 
tumor-derived exosomes.
Because there is no consensus on the use of internal normaliza-
tion control in the serum for miRNA qPCR, the expression levels of 
miR-93 and miR-16 in the serum were examined to be used in data 
normalization. Both miRNAs were proposed as suitable reference 
genes for miRNA quantification in the serum.20 Our results revealed 
that both miR-93 and miR-16 were not readily detected in the exo-
some-enriched fractions of all controls and CRC patients. They did 
not display enough expression levels, high stability, and low vari-
ability. Therefore, they were not used for data normalization.
4. DISCUSSION
Despite recent progresses in the diagnosis and treatment of CRC 
patients, CRC patients die because of distance metastasis. The 
incidence and mortality of CRC in Asia have rapidly increased in 
recent decades. Early detection and surgical removal of primary 
lesions could be helpful in reducing CRC-related deaths and man-
agement of CRC. Carcinogenesis of CRC has been extensively 
studied at the molecular level, but there is a minimal knowledge 
about descriptions of serum exosomal miRNAs in CRC. The 
aim of this study therefore was to investigate the potential of 11 
candidate miRNAs as biomarkers of CRC and the relationship 
between the expression levels of selected miRNAs and clinico-
pathological characteristics of disease. Interestingly, the serum 
levels of miR-301a and miR-23a were found to be upregulated 
in CRC patients compared to normal controls, which were capa-
ble of distinguishing the patients group from the normal group. 
To our knowledge, the present study provides the first evidence 
about the high expression of miR-301a and miR-23 in exosome-
enriched fraction from the serum in CRC. On the other hand, 
with a significant ROC score, miR-23a and miR-301a expression 
levels were able to discriminate the CRC patients from tumor-free 
samples. The study could not validate other candidate miRNAs 
because they could not be measured due to their low sera levels.
One of the most prevalent causes of colorectal cancer is 
mutation in transforming growth factor beta receptor type 
II (TGFBR2). It has been evaluated that approximately 30% 
of colorectal cancers are as a result of mutations in TGFBR2. 
Multiple miRNAs have been approved to implicate in trans-
forming growth factor (TGF)-ß signaling pathway, miR-301a 
has been confirmed to regulate TGFBR2. 21 miR-301a increases 
in various types of cancers and functions as an oncogene-like 
miRNA. miR-301a has been found to increase CRC cell line pro-
liferation, migration, and invasion in vitro and tumor growth in 
vivo. It plays an oncogenic role by reducing the expression of 
cytokine signaling 6 (SOCS6).22 Liu et al. approved upregula-
tion of miR-301a in colon cancer tissues compared to matched 
adjacent normal tissues; they reported oncogenic role of miR-
301a in colon tumorigenesis by regulating transforming growth 
factor TGF-β/smad signaling.23 However, the difference in the 
expression level of miR-301a between CRC and healthy groups 
in blood-based approach has not been elucidated. It is question-
able whether miR-301a can act as an important messenger medi-
ating CRC progression; however, on the basis of previous reports 
on miR-301a in tumor biology, it is supposed that miR-301 has 
a role in poor prognosis and invasion and metastasis in CRC. 
Differential expression of miR-23a was also found in our tested 
CRC patients. miR-23a is one of the top 50 deregulated miRNAs 
in CRC.24,25 A report has shown that miR-23a increases colon 
cancer cell growth, invasion, and metastasis via inhibiting metas-
tasis suppressor gene expression. Furthermore, the upregulation 
of miR-23a expression was correlated with an advanced stage 
and the depth of invasion as well as lymph node metastasis, 
Fig. 2 Serum levels of candidate microRNA (miRNA) biomarkers in the screening phase. Levels of serum miR-23a (A) and miR-301a (B) were compared between 
tumor-free controls and colorectal cancer (CRC) patients.
Fig. 3 Receiver operator characteristic (ROC) curves of miR-30a1 and miR-
23a for discriminating colorectal cancer (CRC) patients from normal subjects.
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demonstrating that miR-23a could be a biomarker for CRC.26 
Similarly, inhibition of miR-23a enhanced 5- fluorouracil (5-FU) 
induced apoptosis by the apoptosis-activating factor-1 (APAF-
1)/caspase-9 apoptotic pathway.27 On the basis of our results, it 
can be suggested that miR-301a and miR-23a have important 
roles in the regulation of CRC invasion and proliferation.
Several studies have attempted to examine the potential roles 
of circulating miRNAs as invasive biomarkers in CRC. Some 
reports have shown the potential roles of miR-17-3p, miR-29a, 
miR-92a, and miR-135b as biomarkers for CRC.12,25,27,28 In this 
regard, Faltejskova et al. used qPCR to evaluate the expres-
sion levels of these four miRNAs in 100 CRC patients and 
30 healthy controls; they did not find any significant change 
in tested miRNAs between the healthy and patient groups.30 
Different groups reported that miR-21, miR-141, miR-29a, 
miR-17-3p, miR-92, miR-601, and miR-760 were significantly 
expressed in a group of patients compared to healthy individu-
als.31,32 Aherne et al. examined the expression of 677 miRNAs 
in CRC and healthy samples; they did not find biomarkers 
found by other groups. They identified two circulating miR-
NAs capable of discriminating groups with different diseases of 
the colon from each other and patients with advanced cancer 
from benign disease groups.29 Therefore, some disparities exist 
among findings of different reports with regard to miRNA bio-
markers; the present findings of upregulation of miR-23a and 
miR-301a in the serum of tested CRC patients were in accord-
ance with previous studies.32–35 In contrast, no significance dif-
ference was observed in the expression of miR-92a, miR-21, 
and other studied miRNAs between the two studied groups. Ng 
et al. demonstrated that miR-92a can distinguish CRC patients 
from healthy controls with 89% and 70% sensitivity and spec-
ificity, respectively.25 Huang et al. also demonstrated similar 
findings (sensitivity: 84, specificity: 71.4).28 In contradiction 
with these findings, Schee et al. showed miR-92a levels to be 
low in several CRC tissue samples and concluded that there 
was no significant association between miR-92a levels and 
CRC.36 In addition, an association has been reported between 
miR-92a expression and other diseases such as breast cancer, 
hepatocellular carcinoma, and cardiovascular diseases.37 It can 
be thus suggested that miR-92a does not have enough spec-
ificity to be a biomarker for CRC. Controversial results are 
also found about expression levels of miR-21 and CRC.3,36,38,39 
Surprisingly, a study revealed that red blood cell (RBC) can 
contribute significant levels of reported cancer biomarkers 
into blood, having significant applications for interpretation of 
biomarkers. A highest tendency for RBC hemolysis in patients 
diagnosed with colon cancer could especially explain the rela-
tively high level of miR-92a in blood samples reported as a bio-
marker in patients with colon cancer. Indeed, several miRNAs 
proposed as circulating cancer biomarkers or used as reference 
genes including miR-21- 5p, miR-16, miR-29a-5p, and 92a-5p 
may generally be driven from blood cells, and their blood levels 
have been shown to be strongly affected by hemolysis.40 There 
are several reasons for the contradictory results reported in the 
literature; for example, studies have evaluated different kinds 
of samples such as colon, rectum, and sigmoid and different 
sample types including serum, plasma, and tissue. Furthermore, 
the genetic background of tumor, ethnic background of patient, 
sample processing, data acquisition, normalization, and analy-
sis may also affect the results. In an effort to control variable 
factors in this study, our tested samples were homogenized in 
terms of age and the stage of disease; the time of sample col-
lection and sample processing was the same as well. In sum-
mary, according to the cycle threshold (Ct) values of the tested 
samples, miR-301a is not a low abundance biomarker in sera. 
The present findings, if validated with a large group of patients, 
could be useful in confirming the role of miRNAs as nonin-
vasive biomarkers for CRC screening. Accordingly, further 
research studies may contribute to the indication of the most 
accurate miRNAs as biomarkers and better understanding of 
their roles in CRC.
In conclusion, 11 miRNAs were investigated in the exosome-
enriched fractions isolated from serum of CRC patients. The 
upregulation of miR-301a in the CRC patients’ serum was not 
surprising; however, no previous study has shown upregulation 
of miR-301a in the CRC serum sample. New potential biomark-
ers, miR-23a and miR-301a, were identified for the diagnosis of 
CRC, which are beneficial for the development of blood-based 
biomarkers for CRC.
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